Lesson plan
TACT411
TACT411 is a monoamine transporter modulator and serotonin 5-HT 1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder. It is being developed by Tactogen. As of the first quarter of 2025, the drug is in the preclinical research stage of development. The exact chemical structure of TACT411 does not yet appear to have been disclosed, but it may be a substituted benzofuran derivative.
Article summary
TACT411 is a monoamine transporter modulator and serotonin 5-HT 1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder. It is being developed by Tactogen. As of the first quarter of 2025, the drug is in the preclinical research stage of development. The exact chemical structure of TACT411 does not yet appear to have been disclosed, but it may be a substituted benzofuran derivative.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.